CHF 2.885 AH: Relief Therapeutics RLF.SW on SIX posts oversold bounce, watch reversal Mar 2026

RLF.SW stock opened an after-hours window at CHF 2.885, marking a short-term bounce after recent weakness. Volume is elevated at 66,704 shares versus an average of 41,210, giving this move traction. The biotech remains volatile after a long down-cycle, but the current price sits near the 200-day average of CHF 2.60558, offering a classic oversold bounce setup for active traders. We outline technical triggers, fundamental context, and scenario-based price targets for Relief Therapeutics on the SIX market.

RLF.SW stock: Market snapshot and immediate action

After hours price is CHF 2.885 on the SIX exchange, up 0.87% from the previous close of CHF 2.86. Day range ran CHF 2.80–3.00 and relative volume is 1.62, which supports a tradable short-term bounce. Market cap stands at CHF 36,280,179 and shares outstanding number 12,575,452 underline small-cap liquidity dynamics that traders must respect.

Technical setup and why this looks like an oversold bounce

Price is trading between the 50-day average CHF 2.9113 and the 200-day average CHF 2.60558, a zone prone to mean reversion after oversold stretches. The stock hit a 52-week low of CHF 1.65 and the 3-month return is +7.249%, suggesting recent buying interest. High relative volume and a close above intraday resistance CHF 2.95–3.00 would confirm a short-term reversal signal for swing traders.

Fundamentals and valuation for Relief Therapeutics (RLF.SW stock)

Relief Therapeutics is a clinical-stage biotechnology firm focused on respiratory and rare disease candidates; cash per share is CHF 0.9958 and book value per share is CHF 2.5997. EPS is negative at -1.36, producing a non-applicable PE and a modest price-to-book of 1.11, which frames a recovery play rather than a value bargain. The company’s current ratio 4.05 and low debt-to-equity 0.06 reduce short-term solvency risk but revenue per share remains small at CHF 0.32296.

Meyka AI grade, forecast and model view on RLF.SW stock

Meyka AI rates RLF.SW with a score out of 100: the model gives a score 64.62 / Grade B — HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects 1‑year CHF 1.728, 3‑year CHF 3.181, and 5‑year CHF 4.859. The 1‑year projection implies a -40.16% downside versus the current CHF 2.885; the 3‑year view implies a +10.3% upside. Forecasts are model-based projections and not guarantees.

Catalysts, upcoming events and sector context

Key near-term catalyst is the earnings/clinical update scheduled 08 Apr 2026, which may reprice risk rapidly. Relief sits in the Healthcare/Biotech sector where average P/E is 26.77 and sector performance has been mixed; biotech-specific trial outcomes drive outsized moves. Watch trial readouts, regulatory updates and any financing announcements as primary upside or downside triggers.

Practical oversold-bounce trading plan and price targets

Short-term traders can treat CHF 2.80 as intraday support and place a stop loss below CHF 2.65 to limit downside on a failed bounce. Initial target: CHF 3.50 (first resistance), mid-case target: CHF 4.50 (retest toward the 52-week high zone). Conservative longer-term target aligned with Meyka AI’s 3‑year forecast is CHF 3.18. Use tight position sizing given the small market cap and 3‑month volatility.

Final Thoughts

RLF.SW stock shows a tradable oversold bounce after-hours at CHF 2.885, backed by elevated volume and a price positioned between the 50-day and 200-day averages. The setup fits an event-driven swing trade ahead of the 08 Apr 2026 earnings and clinical update, but fundamentals remain mixed: EPS -1.36, price-to-book 1.11, and cash per share CHF 0.9958. Meyka AI’s forecast model projects 1‑year CHF 1.728 (implied -40.16%) and 3‑year CHF 3.181 (implied +10.3% vs current price). That divergence highlights two paths: a failed bounce into renewed selling or a successful reversion toward mid-cycle levels. Traders should size positions for volatility, keep stops under CHF 2.65, and watch catalysts closely. Meyka AI’s grade (score 64.62 / B — HOLD) reflects this balanced outlook. Forecasts are model-based projections and not guarantees. For corporate details see Relief Therapeutics’ site and company LinkedIn source source.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.